Apelanio, Mark John S.
HRN: 16-91-90 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/08/2023
CO-AMOXICLAV 625MG (TAB)
01/08/2023
01/14/2023
PO
625
BID
Abrasions
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes